Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Device Center Director Departs; Feigal Oversaw Approval Of Cypher Stent

Executive Summary

CDRH Office of Device Evaluation Director Daniel Schultz, MD, will become acting director of FDA's device center May 1, replacing David Feigal, MD

You may also be interested in...



People In The News: Former Federal Officials On The Move; Changes At Aurinia, Neo, Mallinckrodt, Lilly, And More

Former FDA Commissioner and CMS Administrator Mark McClellan joins the Johnson & Johnson board; former CMS officials Larry Kocot, Mark Hamelburg and Thomas Hutchinson join law firm Epstein Becker & Green; ONCHIT head Farzad Mostashari heads to Brookings; Aurinia names Glickman acting CEO; more personnel moves in this month’s column.

Former FDA device director joins consulting firm

Falls Church-Va. based NDA Partners announces former Center for Device & Radiological Health Director David Feigal, MD, will join as senior partner. Feigal originally joined FDA's Center for Drug Evaluation and Research in 1992; he also worked in the Center for Biologics Evaluation & Research. NDA Partners Chairman Carl Peck, MD, served as CDER director from 1987-1994 and helped recruit Feigal to the agency. Feigal left FDA at the end of April (1"The Pink Sheet" April 19, 2004, p. 5)...

Former FDA device director joins consulting firm

Falls Church-Va. based NDA Partners announces former Center for Device & Radiological Health Director David Feigal, MD, will join as senior partner. Feigal originally joined FDA's Center for Drug Evaluation and Research in 1992; he also worked in the Center for Biologics Evaluation & Research. NDA Partners Chairman Carl Peck, MD, served as CDER director from 1987-1994 and helped recruit Feigal to the agency. Feigal left FDA at the end of April (1"The Pink Sheet" April 19, 2004, p. 5)...

Related Content

UsernamePublicRestriction

Register

PS043758

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel